A phase I single centre 2-part open study to assess the safety and tolerability of AZD2171 following single and multiple oral doses in patients with advanced solid malignant tumours and liver metastases.
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2011
At a glance
- Drugs Cediranib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 20 Jan 2011 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
- 20 Jan 2011 Actual initiation date (Feb 2003) added as reported by ClinicalTrials.gov.
- 13 Aug 2007 New trial record.